A Phase 4 interventional study of Preservative Free Polyethylene glycol 400 0.25% and Propylene Glycol (0.6%) in Dry Eye Disease (DED), sponsored by Andover Research Eye Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Andover Research Eye Institute · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Propylene Glycol in Dry Eye Syndromes — 3 open to participants now, 3 under way, none of them phase 3. Propylene Glycol · Dry Eye Syndromes.
Among the 12 studies testing Propylene Glycol in Dry Eye Syndromes, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is one of 8 in phase 4, and was the 11th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →3 of the 12 studies testing Propylene Glycol in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 20–85
National Taiwan University Hospital · Sites in Taiwan
Ages 20–85
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 60 is close to the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 87 across the 12 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 9 most frequent:
Andover Research Eye Institute is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Andover Research Eye Institute has 1 study filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
1 of the studies testing Propylene Glycol in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06763731National Taiwan University HospitalOptimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery | 2027-01-14 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing Propylene Glycol in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to evaluate the effect of over- the- counter (OTC) lubricating eye drops on tolerability, symptoms and visual outcomes in patients with dry eye disease (DED)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: All ocular exclusion criteria apply to either eye.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Preservative Free Polyethylene glycol 400 0.25%
Drug: Preservative Free Polyethylene glycol 400 0.25%
Drug: Propylene Glycol (0.6%)
Drug: Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%
Drug: Propylene Glycol (0.6%)
4 times daily \[QID\]
Preservative Free Propylene Glycol (0.6%)
QID Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%
Ocular Surface Disease Index (OSDI)
Time frame: 14 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Oct 2026, 4 months after the start.
Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's planned 4 months is below that.
Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Propylene Glycol · Carboxymethylcellulose
Andover Research Eye Institute